Retatrutide is a next-generation investigational peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors
Song C, Fang X, Fang N, Hu F
Being well controlled in the context of type 1 diabetes can seem vague, but as long as your blood sugar is usually in range and you are not experiencing a significant amount of hypoglycemic (low blood glucose) or hyperglycemic (high blood glucose) episodes daily, you can give blood
"PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription"
At Low T Center, we offer free consultations so a provider can help you understand whats going on below the surface and whether PT-141 is a fit for you
Blue Cross Blue Shield of Massachusetts, the state's largest commercial health insurer, is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for weight loss